Analysis of Claims and Patent Landscape for U.S. Patent 10,493,094
What Does U.S. Patent 10,493,094 Cover?
U.S. Patent 10,493,094, granted on December 3, 2019, pertains to a method and system for drug delivery, specifically optimized for targeted, controlled release of pharmaceutical compounds. The patent claims encompass a novel formulation comprising a biodegradable polymer matrix combined with active pharmaceutical ingredients (APIs), designed for minimally invasive administration and sustained release.
Core Claims Breakdown
The patent asserts:
- A delivery system involving a biodegradable polymer matrix encapsulating an API.
- The use of specific polymers — notably poly(lactic-co-glycolic acid) (PLGA) — with precise molecular weight ranges.
- A manufacturing process involving solvent evaporation and lyophilization to produce a particulate delivery system.
- The formulation's ability to provide controlled drug release over a period ranging from days to months.
- A method of implantation that avoids the need for repeated dosing.
The claims are primarily directed at compositions, manufacturing methods, and administration techniques, with emphasis on biocompatibility, release kinetics, and stability.
How Broad Are the Claims?
The scope of patent 10,493,094 is moderately broad:
- It covers a range of biodegradable polymer compositions, not limited to a single polymer type or specific API.
- Claims extend across various drug molecules, with specific examples including chemotherapeutics and hormones.
- Manufacturing claims encompass multiple solvent systems and lyophilization conditions.
- The system's commensurate use in implants, injections, or implantable drug-eluting devices.
However, the claims exclude non-biodegradable polymers, non-lyophilized processes, and formulations with certain specified incompatible excipients. This limits scope in specific directions but grants broad coverage within the biodegradable polymer delivery field.
Patent Landscape and Overlap
Related Patents
The landscape includes numerous patents in controlled-release drug delivery, especially those utilizing PLGA:
| Patent Number |
Title |
Assignee |
Issue Year |
Key Focus |
| US 8,987,123 |
Polymer-based drug delivery systems |
Diffusion Technologies |
2015 |
Extended release formulations |
| US 9,731,540 |
Biodegradable implants |
Biotech Innovators |
2017 |
Controlled release via biodegradable implants |
| US 9,052,381 |
Methods for manufacturing drug-loaded microspheres |
PharmaCo |
2015 |
Microsphere fabrication techniques |
| US 10,088,632 |
Composition for injectable sustained-release drug delivery |
MedForm Labs |
2018 |
Injectable delivery systems |
The patent landscape shows overlap around biodegradable polymer matrices, with previous patents generally focusing on specific polymers, API types, or manufacturing techniques.
Patentability and Freedom-to-Operate
The claims in 10,493,094 face potential challenges due to:
- Prior art on PLGA-based delivery systems, particularly patents predating 2015.
- Similar formulations and processes disclosed in academic publications and patents, such as methods for solvent evaporation or lyophilization.
Freedom-to-operate analyses reveal possible infringement risks when deploying formulations with similar polymer compositions and manufacturing methods, particularly in jurisdictions with expansive prior art.
Critical Analysis of the Claims
Strengths
- The patent's combination of specific polymer molecular weights and manufacturing methods offers tangible innovations over generic controlled-release systems.
- The inclusion of multiple administration routes enhances commercial versatility.
- The formulation's capacity for multi-month release provides a competitive advantage.
Weaknesses and Limitations
- The claims are limited to biodegradable polymers and specific manufacturing techniques, possibly excluding alternative delivery systems using different materials.
- Prior art demonstrates similar controlled-release approaches, potentially narrowing novelty.
- The patent's examples focus on specific APIs, limiting scope for other drug molecules without additional claims.
Opportunities and Risks
- The patent can bifurcate markets involving implantable or injectable drugs with extended release.
- Potential for challenges based on earlier patents related to PLGA formulations and manufacturing techniques.
- The scope may be circumvented by developing formulations using different biodegradable polymers or alternative manufacturing processes.
Market and R&D Implications
The patent's coverage aligns with rising demand for long-acting injectables and implantable drug devices, especially in oncology and hormone therapy. Companies developing biodegradable delivery systems need to assess this patent for licensing opportunities or risk mitigation, particularly if employing similar polymers or manufacturing methods.
Key Takeaways
- Patent 10,493,094 covers a biodegradable, controlled-release drug delivery system with specific claims on polymer composition and manufacturing methods.
- The scope is broad within the biodegradable, polymer-based system category but excludes non-biodegradable approaches.
- Overlap with prior art emphasizes the importance of analyzing ongoing patent filings and existing patents for non-infringement.
- Commercial viability hinges on demonstrating novelty over similar existing controlled-release systems, with particular attention to manufacturing processes and polymer specifications.
- Given the competitive landscape, strategic licensing or inventive design around similar formulations could be necessary.
FAQs
Q1: Can the patent be used for formulations with drugs other than those specified in the examples?
Yes. The claims encompass a range of APIs, though specific examples focus on certain therapeutic classes. However, patent coverage depends on whether the new API falls within the scope of the claims, particularly the formulations' composition and manufacturing methods.
Q2: What jurisdictions does this patent cover?
Primarily the United States. Coverage in other countries depends on corresponding patent applications or grants, as patent rights are territorial.
Q3: How does this patent differ from earlier controlled-release patents?
Its novelty lies in specific polymer molecular weight ranges, manufacturing techniques like solvent evaporation combined with lyophilization, and particular formulations designed for minimally invasive, sustained release.
Q4: Are there known challenges to patentability based on prior art?
Prior art in controlled-release polymers and manufacturing methods presents potential opponents for validity challenges, especially in areas with extensive existing patents. Patent validity would require demonstrating unexpected advantages or technical improvements.
Q5: Are there licensing opportunities for this patent?
Potentially, especially for firms developing biodegradable drug delivery systems that fall within the patent's scope. Licensing would depend on the patent holder's strategic interests and the compatibility of your formulations with the claims.
References
[1] U.S. Patent Office. “U.S. Patent 10,493,094,” December 3, 2019.
[2] Wang, Y., & Li, Q. (2020). Advances in biodegradable polymer drug delivery systems. Drug Development and Industrial Pharmacy, 46(4), 628–639.
[3] Zhang, L., et al. (2019). Manufacturing techniques for controlled-release microspheres. International Journal of Pharmaceutics, 561, 237–247.
[4] US Patent Application Publication. “Methods for manufacturing drug-loaded microspheres,” 2018.
[5] Patel, N., & Green, R. (2021). Patent landscape analysis of PLGA-based drug delivery systems. Journal of Pharmaceutical Innovation, 16(2), 208–222.
